COX-2 as possible target for the inhibition of PGE2 production by Rikko-san activated macrophage

In Vivo

Volumn 22, Issue 3, 2008, Pages 333-336

  Horie, Norio ^a,b   Hashimoto, Ken ^a   Kato, Takao ^b   Shimoyama, Tetsuo ^b   Kaneko, Tadayoshi ^a,c   Kusama, Kaoru ^a   Sakagami, Hiroshi ^a  

^a MEIKAI UNIVERSITY SCHOOL OF DENTISTRY   (Japan)

^b SAITAMA MEDICAL UNIVERSITY   (Japan)

^c TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Cyclooxygenase 1; Cyclooxygenase 2; Kampo medicine; Nitrosylation; Prostaglandin E2; Rikko san

Indexed keywords

ACERINOL; ASARININ; BERGAPTEN; BETA PINEN; BOFU; CIMICIFUGENOL; CIMICIFUGOSIDE; CINEOLE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DAHURINOL; EUCARVOE; GENTIOPICRIN; GENTISIN; GLYCYRRHIZA EXTRACT; HAMAUDOL; HIGENAMINE; KAMPO; LIPOPOLYSACCHARIDE; PLANT MEDICINAL PRODUCT; PROSTAGLANDIN E2; PSORALEN; RIKKO SAN; RYUTAN; SAISHEN; SHOMA; SITOSTEROL; SWERTIAMARIN; TRIFLORASIDE; UNINDEXED DRUG;

ANIMAL CELL; ARTICLE; DRUG MECHANISM; ENZYME INHIBITION; MACROPHAGE ACTIVATION; MOUSE; NONHUMAN; PROSTAGLANDIN SYNTHESIS INHIBITION; PROTEIN EXPRESSION; WESTERN BLOTTING;

EID: 45949104878     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Uematsu Y, Okumura H and Kubota Y: Chinese pain medicine or trigeminal neuralgia and other pain in the maxillofacial area. Shikai Tenbo 61: 817-824, 1983 (in Japanese).
2. Yoshino A, Mori K, Tanaka H, Fukushima M, Yamazaki Y, Takeshima H, Shimada J and Yamamoto Y. The effect of Rikko-san for pain control after tooth extraction. Jpn J Oral Diag Oral Med 13: 107-112, 2000.
3. Odau S, Gabler C, Holder C and Einspanier R: Differential expression of cyclooxygenase 1 and cyclooxygenase 2 in the bovine oviduct. J Endocrinol 191: 263-274, 2006.
4. 2 enzymes. Prostaglandins Other Lipid Mediat 68-69: 3-58, 2002.
5. 2 family. Prog Lipid Res 45: 487-510, 2006.
6. O'Banion MK, Winn VD and Young DA: cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase. Proc Natl Acad Sci 89: 4888-4892, 1992,
7. 2 production by mouse macrophage-like cells. In Vivo 20: 491-497, 2006.
8. Kim SF, Huri DA and Snyder SH: Inducible nitric oxide synthase binds, S-nitrosylates, and activates cyclooxygenase-2. Science 310: 1966-1970, 2005.
9. Seaver B and Smith JR: Inhibition of COX isoforms by nutraceuticals. J Herb Pharmacother 4: 11-18, 2004.
10. Bemis DL, Capodice JL, Anastasiadis AG, Katz AE and Buttyan R: Zyflamend, a unique herbal preparation with nonselective COX inhibitory activity, induces apoptosis of prostate cancer cells that lack COX-2 expression. Nutr Cancer 52: 202-212, 2005.
11. Misko TP, Trotter JL and Cross AH: Mediation of inflammation by encephalitogenic cells: interferon gamma induction of nitric oxide synthase and cyclooxygenase 2. J Neuroimmunol 61: 195-204, 1995.
12. Atar S, Ye Y, Lin Y, Freeberg SY, Nishi SP, Rosanio S, Huang MH, Uretsky BF, Perez-Polo JR and Birnbaum Y. Atorvastatin-induced cardioprotection is mediated by increasing inducible nitric oxide synthase and consequent S-nitrosylation of cyclooxygenase-2. Am J Physiol Heart Circ Physiol 290: 1960-1968, 2006.
13. Horie N, Satoh K, Hashimoto K, Shimoyama T, Kaneko T, Kusama K and Sakagami H: Inhibition by Rikko-san and its major ingredients of LPS-stimulated nitric oxide production by mouse macrophage-like cells. In Vivo 19: 165-172, 2005.
14. 2α through nitric oxide-induced S-nitrosylation: Involvement of inducible nitric oxide synthase and cyclooxygenase-2. J Biol Chem 283: 3077-3087, 2007.
15. 2 extract of Humulus lupulus in vitro and its activity in a mouse model of zymosan-induced arthritis. Planta Med 72: 228-233, 2006.
16. Wu SJ, Tsai JY, Lai MN and Ng LT: Armillariella mellea shows anti-inflammatory activity by inhibiting the expression of NO, iNOS, COX-2 and cytokines in THP-1 cells. Am J Chin Med 35: 507-516, 2007.
17. Lee SH, Son MJ, Ju HK, Lin CX, Moon TC, Choi HG, Son JK and Chang HW: Dual inhibition of cyclooxygenases-2 and 5-lipoxygenase by deoxypodophyllotoxin in mouse bone marrow-derived mast cells. Biol Pharm Bull 27: 786-788, 2004.
18. Li RW, David Lin G, Myers SP and Leach DN: Anti-inflammatory activity of Chinese medicinal vine plants. J Ethnopharmacol 85: 61-67, 2003.
19. Jin DZ, Yin LL, Ji XQ and Zhu XZ: Cryptotanshinone inhibits cyclooxygenase-2 enzyme activity but not its expression. Eur J Pharmacol 549: 166-172, 2006.
20. 2 levels. Biol Pharm Bull 21: 1277-1281, 1998.
21. Coruzzi G, Venturi N and Spaggiari S: Gastrointestinal safety of novel nonsteroidal antiinflammatory drugs: selective COX-2 inhibitors and beyond. Acta Biomed 78: 96-110, 2007.
22. Julémont F, Dogné JM, Pirotte B and de Leval X: Recent development in the field of dual COX/5-LOX inhibitors. Mini Rev Med Chem 4: 633-638, 2004.
23. Kim JS, Kim JC, Shim SH, Lee EJ, Jin W, Bae K, Son KH, Kim HP, Kang SS and Chang HW: Chemical constituents of the root of Dystaenia takeshimana and their anti-inflammatory activity. Arch Pharm Res 29: 617-623, 2006.
24. Bias P, Buchner A, Klesser B and Laufer S: The gastrointestinal tolerability of the LOX/COX inhibitor, licofelone, is similar to placebo and superior to naproxen therapy in healthy volunteers: results from a randomized, controlled trial. Am J Gastroenterol 99: 611-618, 2004.